Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Accumulated Expenses (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Accumulated Expenses for 2 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 53.07% to $7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Dec 2025, down 53.07% year-over-year, with the annual reading at $7.1 million for FY2025, 53.07% down from the prior year.
  • Accumulated Expenses hit $7.1 million in Q4 2025 for Prelude Therapeutics, up from $6.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $15.2 million in Q4 2024 to a low of $3.6 million in Q1 2024.